As shown in Table 1, DLBCL patients with lower circ-APC levels were more likely to exhibit an advanced Ann Arbor stage (p = 0.012), to resist CHOP-like (p = 0.004) and rituximab (p = 0.002) treatment, and to display a low International Prognostic Index (p = 0.032). Here, APC is linked to diffuse large B-cell lymphoma.